Your browser doesn't support javascript.
loading
Totality of evidence refutes neoplasm risk with fezolinetant - Authors' reply.
Douxfils, Jonathan; Beaudart, Charlotte; Dogné, Jean-Michel.
Afiliación
  • Douxfils J; Clinical Pharmacology and Toxicology Research Unit, Department of Pharmacy, Namur Research Institute for Life Sciences, Faculty of Medicine, University of Namur, Namur 5000, Belgium; QUALIblood, Namur, Belgium; Department of Biological Hematology, CHU Clermont-Ferrand, Hôpital Estaing, Clermont-Ferrand, France. Electronic address: jonathan.douxfils@unamur.be.
  • Beaudart C; Clinical Pharmacology and Toxicology Research Unit, Department of Pharmacy, Namur Research Institute for Life Sciences, Faculty of Medicine, University of Namur, Namur 5000, Belgium; WHO Collaborating Center for Epidemiology of Musculoskeletal Health and Aging, Division of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium.
  • Dogné JM; Clinical Pharmacology and Toxicology Research Unit, Department of Pharmacy, Namur Research Institute for Life Sciences, Faculty of Medicine, University of Namur, Namur 5000, Belgium.
Lancet ; 403(10440): 1988, 2024 May 18.
Article en En | MEDLINE | ID: mdl-38762323
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tiadiazoles / Compuestos Heterocíclicos con 2 Anillos / Neoplasias Límite: Humans Idioma: En Revista: Lancet Año: 2024 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tiadiazoles / Compuestos Heterocíclicos con 2 Anillos / Neoplasias Límite: Humans Idioma: En Revista: Lancet Año: 2024 Tipo del documento: Article